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Abstract
Purpose—The aim of this study was to determine the association between urinary isoflavonoid
(genistein, daidzein, and the daidzein metabolites O-desmethylangolensin (O-DMA) and equol)
excretion and markers of inflammation in adults in the United States in National Health and
Nutrition Examination Survey (NHANES) 2005–2008.
Methods—The NHANES is a cross-sectional study conducted by the National Center for Health
Statistics to study the health and nutritional status of people living in the United States. The
analysis included 1,683 participants from study years 2005–2008 for whom urinary isoflavonoids
were measured and who met inclusion criteria. Urinary isoflavonoids were measured by HPLC-
APPI-MS/MS. Serum C-reactive protein (CRP) was measured by latex-based nephelometry.
White blood cell (WBC) count was measured by Coulter counting. Multivariable linear regression
was used to calculate the geometric mean values of the markers, and multivariable logistic
regression was used to estimate the odds of high CRP (≥3 mg/L) and of high WBC count (≥7,900/
μL) by quartile of urinary isoflavonoid (nmol/mg creatinine).
Results—The highest quartile of genistein (OR = 0.62; 95 % CI 0.39–0.99) was associated with
significantly decreased odds of high CRP compared with the lowest quartile. The sum of daidzein
and its metabolites was significantly inversely associated with serum CRP concentration (p-trend
= 0.017). Equol was inversely associated with WBC count (p-trend <0.0001). O-DMA was the
only isoflavonoid whose excretion was significantly associated with a decrease in both CRP (p-
trend = 0.024) and WBC count (p-trend <0.0001).
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Conclusions—Though no clear pattern emerged, higher excretion of certain soy isoflavonoids
was associated with decreased CRP concentration and WBC counts, suggesting a possible inverse
association between soy intake and inflammation.
Keywords
Soy isoflavonoids; Inflammation; C-reactive protein; White blood cell count; Cross-sectional
studies
Introduction
The World Cancer Research Fund and American Institute for Cancer Research estimate that
suboptimal diet, physical activity, and body fatness are responsible for one-third of all
cancers [1], and others have estimated that approximately 80 % of colorectal cancers can be
attributed to suboptimal diet [2]. Therefore, modification of the diet may be an effective
strategy to reduce cancer burden. Individual nutrients or functional foods containing
biologically active components can influence cancer-related processes, including
inflammation [3]. Inflammation is an important driver of tumor progression and therefore
development of cancers, including colorectal cancer. The chronic inflammatory bowel
diseases, Crohn’s disease, and chronic ulcerative colitis are associated with increased risk of
colorectal cancer [4]. Additionally, use of non-steroidal anti-inflammatory drugs (NSAIDs)
is associated with decreased risk of colorectal cancer and NSAIDs including sulindac and
celecoxib reduced the occurrence of recurrent adenomas and reduced the occurrence of
colorectal cancer in patients with familial adenomatous polyposis [5–9].
C-reactive protein (CRP), an acute phase response protein, was traditionally used to monitor
inflammation in people with chronic inflammatory conditions. More recently, CRP has been
recommended as a tool to assess cardiovascular disease risk [10]. Prospective studies and
systematic reviews suggest that higher levels of CRP may also be associated with increased
risk of colorectal cancer [11–16]. Similarly, elevated white blood cell (WBC) count is a
marker of systemic inflammation, and elevated levels are positively correlated with risk of
cardiovascular events and various cancers [17, 18]. CRP concentration and WBC count,
while components of non-specific systemic responses, can be useful biomarkers because
they are easy to measure, they do not have diurnal or seasonal variation, and their levels are
not affected by recent meals. However, CRP levels and WBC counts are very responsive to
acute infections such as colds and are influenced by smoking, obesity and other chronic
disease risk factors [15].
One functional food receiving much attention for its anti-cancer and anti-inflammatory
activities is soy. Recent meta-analyses showed that consumption of soy foods was associated
with decreased risk of breast cancer, though these associations were stronger in Asian
populations than in Western populations. Menopausal status also appeared to be an
important effect modifier, as the associations were stronger among postmenopausal women
[19, 20]. Soy’s anti-cancer and anti-inflammatory activities can be partially attributed to its
isoflavonoid content [21]. Soy isoflavonoids are phytoestrogens that can bind to estrogen
receptor (ER) α and with even higher affinity to ERβ [22]. Genistein (40–60 %), daidzein
(35–50 %), and glycitein (4–12 %) are the major isoflavones in soy and soy products [23].
Daidzein can be metabolized by intestinal bacteria to O-desmethylangolensin (O-DMA) and
equol, both of which are bioavailable and also have estrogenic activities. Approximately 80–
90 % of humans have the capability to produce O-DMA and 30–50 % can produce equol
[24].
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While oral estrogen use via hormone replacement therapy in postmenopausal women
increases multiple markers of inflammation, including CRP [25], the effects of
phytoestrogens such as isoflavonoids on inflammation are not well characterized.
Randomized controlled trials to determine any anti-inflammatory activities of soy
isoflavonoids in humans have resulted in mixed findings. While a few studies show
decreases in some, but not all, inflammation markers studied [26, 27], many show no
changes in any inflammatory markers with 6 weeks to 2 years of various soy isoflavonoid
interventions [28–35]. The majority of these trials did not control for the soy or isoflavonoid
content of the background diets of the participants, and only a few asked the participants to
keep food diaries. These studies are also limited in that they supplemented participants’ diets
with high amounts of partially or completely isolated isoflavonoids and therefore cannot
address the effects of biologically relevant amounts of soy isoflavonoids from food sources.
In this study, our aim was to determine the relationship between urinary isoflavonoids and
high serum CRP level or WBC count in adults in the United States. We hypothesized that
urinary isoflavonoids and the inflammation markers would be inversely related.
Methods
Study population
The National Health and Nutrition Examination Survey (NHANES) is a cross-sectional
study conducted by the National Center for Health Statistics to study the health and
nutritional status of people living in the United States [36]. Our analysis includes data from
the 2005–2006 and 2007–2008 NHANES cycles. Because the method for isoflavonoid
analysis changed following the 2003–2004 cycle, we limited our analysis to data from 2005
to 2008. The 2005–2006 survey examined a nationally representative sample of 10,348
people, with oversampling of low-income persons, adolescents 12–19 years of age, persons
over 60 years of age, Mexican Americans, and African Americans. The 2007–2008 cycle
examined 10,149 people with similar oversampling except that all Hispanic persons were
oversampled as well. Urinary isoflavonoid concentrations were measured in 2,528 persons 6
years of age and older in 2005–2006 and in 2,424 persons 6 years of age of older in 2007–
2008.
We restricted the analysis to participants 18 + years old (n = 3,428) to reduce variability in
inflammation marker levels. From these, we excluded participants based on other factors
that would increase variability of inflammation markers or lead to extreme CRP/WBC
values: pregnancy (n = 129), current use of female hormones (n = 184), poor health status (n
= 108), or acute infection at the time of the examination, including head or chest colds (n =
484), stomach or intestinal illness (n = 173), flu, pneumonia, or ear infection (n = 37), or
whether a doctor or health professional has ever told the participant whether he/she has
diabetes (n = 222), pre-diabetes (n = 88), or kidney disease (n = 26). These exclusion criteria
were reported by participants during the interview, and pregnancy status was also verified
by a laboratory test. Individuals with CRP values that were missing (n = 106) or >10 mg/L
(n = 138) or WBC counts that were missing (n = 1), >11,700 (n = 41), or <3,000/μL (n = 8)
were excluded because these extreme values likely reflect acute, and not chronic,
inflammation [37, 38]. The final sample size for this study was 1,683 individuals.
Measurements
Blood was collected by venipuncture and spot urine samples were collected at NHANES
mobile examination centers (MEC). Samples were processed, stored at −20 °C, and shipped
to analytic laboratories. Urinary concentrations of isoflavonoids were measured by HPLC-
APPI-MS/MS by the Nutritional Biomarkers Branch, the Division of Laboratory Sciences,
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National Center for Environmental Health, Centers for Disease Control and Prevention.
Briefly, urine samples were processed using enzymatic deconjugation of the glucuronidated
isoflavonoids, and size-exclusion filtration was used. Isoflavonoids were separated by
reverse-phase HPLC, detected by APPI-MS/MS, and quantified by isotope dilution. Urinary
concentration of creatinine, used to correct urinary levels of analytes for urine dilution, was
measured using Beckman Synchron CX3 Clinical Analyzer at the University of Minnesota.
CRP was measured by latex-based nephelometry by the Immunology Division, Department
of Laboratory Medicine, University of Washington Medical Center. Particles of a
polystyrene core and a hydrophilic shell were used to link anti-CRP antibodies covalently.
CRP present in test samples formed antigen–antibody complexes with the latex particles,
and light scattering was proportional to the concentration of CRP present in the sample.
Quality control during sample collection and analysis was monitored by unscheduled visits
to collection and laboratory sites. Blind split samples were analyzed and laboratories
randomly conducted repeat testing on 2.0 % of all samples. In addition, all quality control
methods recommended by manufacturers were followed [36].
We normalized isoflavonoid concentrations to creatinine concentration by dividing values to
account for variability between participants in urine dilution [39, 40]. CRP measurements ≥3
mg/L were categorized as “high CRP”; values <3 mg/L were categorized as “low CRP”
based on The American Heart Association and Centers for Disease Control and Prevention
cutpoint for being at high risk for cardiovascular disease [41]. Further, previous studies on
CRP and colorectal cancer have also typically used these cutoff values [11, 13, 14, 42].
Values at or below the CRP limit of detection of 0.2 mg/L were reported as 0.1 mg/L. WBC
count was determined using Beckman Coulter MAXM instruments in MECs with the
Beckman Coulter method of counting and sizing. Participants with WBC counts ≥7,900/μL
(but ≤11,700) were classified as “high WBC count,” and those with values <7,900/μL (but
≥3,000) were classified as “low WBC.” Similar cutpoints were used in previous studies that
reported a hazard ratio for lung cancer incidence of 2.81 (95 % CI 1.58–5.01) for those with
WBC cell counts ≥8,000/μL compared with those with counts <6,400/μL [17] or an 89 %
increase in total cancer mortality comparing those with WBC counts ≥7,400/μL to those
with counts ≤5,300/μL [43].
Weight, height, and waist circumference were measured by trained health technicians at
MECs. Body mass index (BMI) was calculated as weight in kg divided by squared height in
m. Age, sex, alcohol use, smoking habits, physical activity, statin drug use, prescription
NSAID use, and household income were self-reported and assessed via interview. Race/
ethnicity was also self-reported via interview, and participants were asked to identify as
Mexican American, other Hispanic, non-Hispanic white, non-Hispanic black, or “other race
—including multiracial.”
Menopausal status of women was determined using criteria from Kalkwarf et al. [44]
adapted to this study, which excludes women taking birth control pills. First, females over
60 were categorized as postmenopausal, and remaining unclassified females with bilateral
oophorectomies were also categorized as postmenopausal. Remaining unclassified females
who have had a period or pregnancy in the past 12 months or with age <50 years were
categorized as premenopausal, and then, remaining unclassified females with age >50 were
categorized as postmenopausal.
Statistical analyses
Data were analyzed using survey methods in Stata statistical software version 12.1 (College
Station, TX) to account for the complex NHANES sampling design [36]. Data were first
explored using descriptive statistics. We then estimated odds ratios (ORs) of high CRP (≥3
mg/L) or high WBC count (≥7,900/μL) by quartiles of normalized isoflavonoid
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concentration (nmol or pmol per mg creatinine) using logistic regression and calculated
geometric means of CRP concentration and WBC count by isoflavonoid quartile using linear
regression. In the demographics-adjusted model, we adjusted for sex, age (continuous), and
race/ethnicity (non-Hispanic white, non-Hispanic black, Hispanic/Mexican American,
other). In the multivariable model, we further adjusted for BMI (<18.5; 18.5–24.9; 25.0–
29.9; ≥30), waist circumference (continuous), alcohol use (average number of drinks/d,
indicator variables), menopausal status, physical inactivity (<500 MET-min/week or ≥500
MET-min/week), cigarette smoking status (never, former, or current smoking), and annual
household income (increments of $5,000/year, ordinal). These covariates were chosen a
priori based on known or suspected confounders of the relationship of isoflavonoids and
inflammation. The p-trend was obtained by modeling the median value for each quartile of
normalized isoflavonoids as a continuous variable.
Results
Table 1 shows the characteristics of the study population overall and by CRP status for the
1,683 participants. The mean age of study participants was 45.3, 45 % were female, and 72
% were non-Hispanic white. The 75th percentile of CRP concentration was 3 mg/L.
Compared with those with low CRP, participants with high CRP (≥3 mg/L) were older, were
more likely to be non-white, had higher BMI and waist circumference, were less physically
active, drank fewer alcoholic drinks per day, and had a lower annual household income. The
distribution of smoking status and the proportion of participants using statins or prescription
NSAIDS were similar between the two groups. Similar patterns to high versus low CRP
were observed when comparing participants with high to low WBC counts (Table 2), except
that those with high WBC count drank similar numbers of alcoholic drinks per day (p =
0.75), were more likely to be current smokers (40.2 vs. 18.1 %, p <0.0001) or to be self-
classified as non-Hispanic white (76.0 vs. 70.9 %, p = 0.048), and less likely to be former
(18.5 vs. 26.9 %, p = 0.01) or never smokers (41.3 vs. 55.0 %, p = 0.0007), or to be self-
classified as “other” race (3.4 vs. 7.3 %, p = 0.007).
Demographics (sex, age, and race/ethnicity)-adjusted and multivariable-adjusted ORs for
high versus low CRP by quartile of isoflavonoid excretion are shown in Table 3.
Demographics-adjusted ORs for each quartile compared with the lowest quartile showed
general trends toward decreased odds of high CRP with higher isoflavonoids, though these
results were not statistically significant. Adjustment for NHANES cycle did not alter the
findings, and cycle-specific results were similar to the combined findings (data not shown).
After further adjustment for menopausal status, waist circumference, BMI, physical activity,
alcohol use, smoking status, and household income (multivariable-adjusted model), the
highest quartile of genistein was significantly associated with decreased risk of high CRP
(OR = 0.62, 95 % CI 0.39–0.99), and the second, third, and fourth quartiles of daidzein were
associated with decreased risk of high CRP, though the only statistically significant
reduction was observed in the third quartile (OR = 0.59, 95 % CI 0.35–0.98). While no other
isoflavonoid was significantly associated with decreased odds of high CRP, genistein,
daidzein, the sum of daidzein and its metabolites, and the sum of all four isoflavonoids all
showed general trends toward decreased ORs of high CRP for quartiles 2, 3, and 4 versus
quartile 1. However, post hoc analyses comparing quartiles 2–4 to quartile 1 for these
isoflavonoids did not result in a statistically significant decrease in odds of high CRP (data
not shown).
We calculated the geometric mean CRP concentration by quartiles of urinary isoflavonoids
using the multivariable-adjusted model (Table 3). The highest quartiles of O-DMA and of
daidzein + O-DMA + equol were significantly inversely associated with serum CRP levels,
and significant decreasing trends were observed (p-trend = 0.024 and 0.017, respectively).
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O-DMA was also associated with significantly decreased geometric mean WBC counts in
the third (6,920 cells/μL, p <0.05) and fourth (6,760 cells/μL, p <0.001) quartiles compared
with the lowest quartile (7,060 cells/μL) and with an overall decreasing trend (p-trend
<0.0001) (Table 4). Equol, while not associated with decreases in CRP levels, was
associated with decreased geometric mean WBC counts comparing the highest quartile to
the lowest (6,760 vs. 7,020 cells/μL, p <0.0001) and with decreasing WBC count with
increasing equol (p-trend <0.0001). The ORs of high WBC count associated with the
second, third, or fourth quartiles of O-DMA and equol were non-significantly decreased in
both the demographics- and multivariable-adjusted models. Genistein, daidzein, the sum of
daidzein and its metabolites, or of all four isoflavonoids were not associated with
statistically significant changes in WBC count.
Discussion
While we found no overall patterns of associations between urinary isoflavonoids and serum
CRP or WBC count, genistein, daidzein, O-DMA, and daidzein plus its metabolites were
associated with decreasing CRP to varying degrees, while O-DMA and equol were
associated with decreasing WBC count, suggesting a possible inverse association between
certain isoflavonoids and inflammation.
To our knowledge, this is the first observational analysis examining the association between
urinary isoflavonoids and inflammation markers. A recent cross-sectional analysis in
Chinese women showed that soy intake in the past year was inversely associated with two
out of eight inflammatory markers examined and that soy intake in the past 24 h was
associated with inverse relationships with five out of eight markers, including interleukin-6,
inter-leukin-1β, tumor necrosis factor α (TNFα), and TNFα receptors 1 and 2 [45]. Soy food
intake was not inversely associated with CRP levels in this study, and elevated WBC count
was not examined. Our findings are consistent with this study because we found that
isoflavonoids are not similarly associated with different inflammatory markers. However,
our study differs in that we examined individual urinary isoflavonoids, which are more
representative of biologically effective doses of isoflavonoids, and not dietary soy intake.
The cutoff values for high versus low CRP and WBC count were chosen based on reports of
increased risk of colorectal and other cancers for individuals with similar or higher values
[11, 18, 46–48]. A recent meta-analysis showed that a 1-unit increase in ln-transformed CRP
concentration is associated with a relative risk of colorectal cancer of 1.12 (95 % CI 1.02,
1.26) [16]. Had we categorized CRP or WBC differently in the present analysis, we might
have observed differences in the magnitude of the association with urinary isoflavonoid
quartiles.
This study has several strengths for studying the associations of urinary isoflavonoids with
markers of inflammation. First, we used NHANES 2005–2008, a nationally representative
sample of individuals. In addition, creatinine-normalized urinary isoflavonoid values
integrate isoflavonoid intake from all sources, which is challenging to capture via food
frequency questionnaires or 24-h recalls, particularly in populations with low soy intake. For
example, using NHANES data from 2001 to 2004, Frankenfeld [49] demonstrated that
consumption of milk and milk products, but not of legumes, was a significant correlate of
urinary equol levels, which likely reflected equol intake from milk. Further, the ubiquity of
soy products, particularly hidden soy products, in the diets of adults in the United States can
result in inaccurate recall of soy intake. The use of urinary isoflavonoid measurements also
captures individuals’ ability to process daidzein to equol or O-DMA. Another strength of
this study is the use of latex-based nephelometry to measure serum CRP in NHANES 2005–
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2008. This method has a much lower limit of detection than methods used in previous
NHANES surveys.
This study also has some important limitations. First, our analysis, like all cross-sectional
analyses, is subject to residual confounding and lack of temporality. Another limitation is
the narrow range of isoflavonoid exposure in the US population. Habitual consumption of
foods high in isoflavones is rare in this population as whole and is only expected in
population subgroups, including Asian Americans. However, NHANES includes Asian
American race in the “other” race/ethnicity category, which comprises only 6 % of the
population. Therefore, it is difficult to examine the effects of very high isoflavonoid
exposure. To address this limitation, we conducted post hoc analyses comparing the highest
quartile of isoflavonoid exposure to the sum of quartiles 1–3 or comparing the sum of
quartiles 2–4 to the lowest quartile of exposure, but these analyses did not yield any
significant results (data not shown).
The excretory half-life of soy isoflavonoids ranges from 3 to 10 h [39]. Because NHANES
only collected spot urine samples at one point in time, the urinary isoflavonoid
concentrations in our analysis only represent very recent soy intake. However, in two
separate studies, one in a middle-aged and older Chinese population in Singapore with high
daily soy intake and one in a multi-ethnic population of women, biomarkers in spot urine
samples taken on random dates correlated well with overall soy intake [50, 51]. In a
randomized, double-blinded, placebo-controlled trial testing effects of supplemental soy
protein on 350 postmenopausal women, spot urine isoflavonoid levels displayed high
correlation with plasma isoflavonoid levels (between-subject Pearson correlation median r =
0.80) [52]. Urinary isoflavonoid levels have also been reported to correlate well with serum
isoflavonoid levels in a cross-sectional sample of participants not randomized to consume
supplemental soy [39]. These high correlations of plasma and urine isoflavonoid levels
suggest that the amounts observed in the urine will approximate the biologically effective
doses of these compounds. Future studies should focus on using multiple urinary
isoflavonoid measurements over time to investigate the relationship with inflammation.
The plasma half-life of CRP is approximately 19 h [15]. While CRP values are not
influenced by recent food intake, CRP is part of a non-specific inflammatory response and
its concentration could be influenced by recent infection, surgery, medications, autoimmune
diseases, and other acute or chronic conditions. We excluded those with self-reported acute
infections, poor health status at the time of examination, or select chronic conditions, but
there could still be residual confounding from medications or other conditions.
Most variables included in our final models and for exclusion criteria were reported by
participants during the interview, including race/ethnicity, physical activity, smoking status,
household income, and current health status and conditions. Inaccurate recall and
misclassification are possible with these variables. In addition, NHANES’ “other” race/
ethnicity category includes Asian Americans, who have higher average soy intake and lower
average inflammatory marker levels than those of other race/ethnicity groups in the United
States [53–55]. Further, participants were asked to identify with one only one race/ethnicity
category, and those who identified with multiple were classified as “other.” Because
NHANES does not collect more detailed race/ethnicity information, we cannot rule out
residual confounding due to incomplete classification.
In conclusion, the results of our study showed that excretion of select isoflavonoids was
associated with decreased odds of high inflammatory markers and with decreasing
circulating levels of the markers. O-DMA was the only isoflavonoid whose excretion was
inversely associated with circulating levels of both CRP and WBC count. This cross-
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sectional analysis suggests possible inverse associations between soy intake and
inflammation, though no clear patterns of associations with individual isoflavonoids
emerged. Future prospective cohort studies with multiple measurements of isoflavonoids
and inflammatory markers will help to clarify the relationship between soy isoflavonoids
and inflammation, which will help to inform whether dietary soy can decrease the risk of
cancer and other inflammation-associated diseases.
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